![]() ![]() ![]() |
FDA
Home Page | CDRH Home Page | Search
| CDRH
A-Z Index | Contact CDRH
|
PMA Final Decisions Rendered for November 2002 |
![]() |
A PDF document that contains the "Approval letter and Summary of Safety and Effectiveness" is being added to this listing for each PMA. The PMA number will appear as a link if this document is available. Information about the PDF Reader is available. November 2002 PMA Monthly Approval List
PMA Original Approvals
11/27/02 |
ALERT® System (ALERT® Catheter, ALERT® Interface Cable, and ALERT® Companion™ with Software Version 1.08) |
EPMed Systems, Inc. West Berlin, NJ 08091 |
Approval for the ALERT System (ALERT Catheter, ALERT Interface Cable, and ALERT Companion with Software Version 1.08). The ALERT System is indicated for use in patients who are candidates for transvenous electrical cardioversion for the treatment of atrial fibrillation. |
11/6/02 |
EXCLUDER™ Bifurcated Endoprosthesis |
W.L. Gore & Associates, Inc. Flagstaff, AZ 86001 |
Approval for the EXCLUDER™ Bifurcated Endoprosthesis. The EXCLUDER™ Bifurcated Endoprosthesis is intended to exclude the aneurysm from the blood circulation in patients diagnosed with infrarenal abdominal aortic aneurysms (AAA) disease and who have appropriate anatomy as described: 1) Adequate iliac/femoral access 2) Infrarenal aortic neck treatment diameter range of 19-26 mm and a minimum aortic neck length of 15 mm 3) Proximal aortic neck angulation ≤ 60 º 4) Iliac artery treatment diameter range of 8-13.5 mm and iliac distal vessel seal zone length of at least 10 mm. The Aortic and Iliac Extender Endoprostheses are intended to be used after deployment of the EXCLUDER Bifurcated Endoprosthesis. These extensions are intended to be used when additional length and/or sealing for aneurismal exclusion is desired. |
11/7/02 |
VERSANT™ HCV RNA Qualitative Assay |
Gen-Probe Inc. San Diego, CA 92121 |
Approval for the VERSANT™ HCV RNA Qualitative Assay. The device is indicated for: The VERSANT™ HCV RNA Qualitative Assay is an in vitro nucleic acid amplification assay for the detection of hepatitis C virus (HCV) RNA in human plasma (EDTA, sodium heparin, sodium citrate, and ACD) or serum. The VERSANT™ HCV RNA Qualitative Assay is indicated for use with fresh or frozen specimens from the following populations: individuals with antibody evidence of HCV infection with evidence of liver disease, and individuals suspected to be actively infected with HCV with antibody evidence, and individuals at risk for HCV infection with antibodies to HCV. Detection of HCV RNA is evidence of active HCV infection. |
11/4/02 |
Essure™ System |
Conceptus, Inc. San Carlos, CA 94070 |
Approval for the Essure™ System. The device is indicated for permanent birth control (female sterilization) by bilateral occlusion of the fallopian tubes. |
PMA Supplemental Approvals
P830037/S047 11/26/02 Real-Time |
FreshLook® Radiance Spherical and Toric (phemfilcon A) Soft Contact Lenses |
CIBA Vision Corporation Duluth, GA 30097 |
Approval for an additional colorant to be used in the colorant process and a revision to the labeling to move the statement “the lens acts to enhance or alter the apparent color of the eye” from the Actions section of the package insert to the Indications section. The device, as modified, will be marketed under the Freshook® trade name with the following indications: Vision Correction Spherical: FreshLook® spherical (phemfilcon A) soft (hydrophilic) contact lenses are indicated for the correction of visual acuity in persons with non-diseased eyes that are myopic (nearsighted) or hyperopic (farsighted) and may exhibit refractive astigmatism of up to 2.0 diopters that does not interfere with visual acuity. The lens acts to enhance or alter the apparent color of the eye. Toric FreshLook® Toric (phemfilcon A) soft (hydrophilic) contact lenses are indicated for the correction of visual acuity in persons with non-diseased eyes that are myopic (nearsighted) or hyperopic (farsighted) and may exhibit refractive astigmatism of up to 6.0 diopters. The lens acts to enhance or alter the apparent color of the eye. The lenses may be prescribed for Daily Wear or Extended Wear in not-aphakic persons from 1 to 7 days between removal for cleaning an disinfection or disposal, as recommended by the eye care professional or for Daily Wear in aphakic persons. The eye care professional may prescribe the lens in either the single-use disposable wear or for frequent replacement with cleaning, disinfection and scheduled replacement. When prescribed for frequent replacement, the lens may be disinfected using a chemical disinfection system. FreshLook soft contact lenses with UV-absorbing monomer help protect against transmission of harmful UV radiation to the cornea and into the eye. |
P850048/S017 11/27/02 180-Day |
Access Hybritech PSA on the Access 2 Immunoassay Analyzer |
Beckman Coulter, Inc. Chaska, MN 55318 |
Approval for the Access Hybritech PSA on the Access 2 Immunoassay Analyzer. The device is indicated for: The Access Hybritech PSA assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of total prostate specific antigen (PSA) in human serum using the Access Immunoassy Systems. The device is indicated for the measurement of serum PSA in conjunction with digital rectal examination (DRE) as an aid in the detection of prostate cancer in men aged 50 years or older. Prostate biopsy is required for diagnosis of cancer. The device is further indicated for the serial measurement of PSA to aid in the prognosis and management of patients with prostate cancer. |
P860003/S041 11/25/02 180-Day |
UVAR XTS Photopheresis System |
Therakos, a Johnson & Johnson Company Exton, PA 19341 |
Approval for a new manufacturing facility located at Mack Molding Company, Arlington, Vermont. The facility will manufacture the XTS Instrument and XT20 light assembly. |
P860019/S179 11/20/02 180-Day |
Maverick2™ Monorail™ PTCA Catheter |
Boston Scientific SCIMED, Inc. Maple Grove, MN 55311 |
Approval for the Maverick2™ Monorail™ PTCA Catheter. The device, as modified, will be marketed under the trade name Maverick2™ Monorail™ PTCA Catheter and is indicated for balloon dilatation of the stenotic portion of a coronary artery or bypass graft stenosis for the purpose of improving myocardial perfusion. The Maverick2™ balloon catheter (2.25 – 4.00 mm) is also indicated for the post delivery expansion of balloon expandable stents. |
P860019/S186 11/21/02 135-Day |
Maverick™ OTW, Maverick™ Monorail ™& Maverick2™ Monorail™ PTCA Catheters |
Boston Scientific SCIMED, Inc. Maple Grove MN 55311 |
Approval for a modification of the laser welding process for the Maverick™ OTW, Maverick™ Monorail ™& Maverick2™ Monorail™ PTCA Catheters. |
P860019/S189 11/6/02 Special |
Boston Scientific/SCIMED PTCA Catheters: NC Monorail™, NC Big Ranger ™, NC Ranger™ 15 mm, NC Ranger™ 22/25/30 mm, NC Ranger™ 16/18 mm and NC Ranger™ 9mm |
Boston Scientific SCIMED, Inc. Maple Grove MN 55311 |
Approval for an additional instruction in the Directions for Use Manual in order to enhance safe device use. |
P860019/S190 11/25/02 180-Day |
SCIMED ACE, ACE 1 cm Tip, Long ACE, Graft ACE, Pivot, Trapper, Surpass, and Remedy PTCA Catheters |
Boston Scientific Scimed, Inc. Maple Grove, MN 55311 |
Approval for an alternate sterilization facility located at Cosmed Group, Inc., Coventry, Rhode Island. |
P900009/S014 11/18/02 Real-Time |
Exogen 2000+ Sonic Accelerated Fracture Healing System |
Smith and Nephew, Inc. Memphis, TN 38116 |
Approval for labeling changes to the Physician’s Instructions for Use. |
11/6/02 Panel |
Thoratec HeartMate Sutures Not Applied Vented Electric Left Ventricular Assist System (SNAP VE LVAS) |
Thoratec Corporation Pleasanton, CA 94588 |
Approval for an expanded Indication for Use for the Thoratec HeartMate SNAP VE LVAS. The device is indicated for use as a bridge to cardiac transplantation in cardiac transplant candidates at risk of imminent death from nonreversible left ventricular failure. It is now also indicated for use in patients with New York Heart Association Class IV end stage left ventricular Failure who have received optimal medical therapy for at least 60 of the last 90 days, and who have a life expectancy of less than two years, and who are not eligible for cardiac transplantation. The device system is approved for use both inside and outside of the hospital. |
P940022/S026 11/1/02 Real-Time |
CLARION® CII Bionic Ear System (Adult) |
Advanced Bionics Corporation Sylmar, CA 91342 |
Approval for the following changes to the postmarket study protocol: 1) Use of only the PB-K Test to determine candidacy in children 4 years through 17 years of age at time of implant. 2) Substitution of the PB-K Test for the ESP Test as an outcome measure. 3) Division of the youngest age group into two groups. 4) Additional inclusion/exclusion criteria for adults and children. |
P940022/S027 11/6/02 Real-Time |
CLARION® CII Bionic Ear System (Adult) |
Advanced Bionics Corporation Sylmar, CA 91342 |
Approval for a revision to the Package Insert (Document Number 9196252-001) that modified the percentage of patients who preferred High Resolution Sound Processing to conventional sound processing. This modification is based on updated data received from patients at the 12-month follow-up visit which showed that three of the five patients who originally preferred their conventional strategy at the three-month experimental strategy visit switched their preference to HiRes. Thus, 48 of 50 patients (96%) ultimately preferred HiRes. |
P950005/S015 11/13/02 180-Day |
NAVISTAR™ Deflectable Tip Diagnostic/Ablation Catheters |
Biosense Webster Diamond Bar, CA 91765 |
Approval for the sterilization facility located at Cosmed of California, San Diego, California. |
P960011/S007 11/1/02 180-Day |
BioLon |
Bio-Technology General Corp. Iselin, NJ 08830 |
Approval for a new sterilization facility located at Mediplast Israel, Ltd., Yavnem, Israel |
P960043/S042 11/12/02 Real-Time |
Perclose® A-T 6 Fr. Suture Mediated Closure (SMC) System |
Perclose, Inc. Redwood City, CA 94063 |
Approval for expanding the Indications for Use of the Closer A-T 6 Fr. SMC System to include 7 and 8 Fr. sheath sizes and to change the labeling to include <0.038” guidewires. |
P960058/S026 11/1/02 Real-Time |
CLARION® CII Bionic Ear System (Pediatric) |
Advanced Bionics Corporation Sylmar, CA 91342 |
Approval for the following changes to the postmarket study protocol: 1) Use of only the PB-K Test to determine candidacy in children 4 years through 17 years of age at time of implant. 2) Substitution of the PB-K Test for the ESP Test as an outcome measure. 3) Division of the youngest age group into two groups. 4) Additional inclusion/exclusion criteria for adults and children. |
P960058/S027 11/6/02 Real-Time |
CLARION® CII Bionic Ear System (Pediatric) |
Advanced Bionics Corporation Sylmar, CA 91342 |
Approval for a revision to the Package Insert (Document Number 9196252-001) that modified the percentage of patients who preferred High Resolution Sound Processing to conventional sound processing. This modification is based on updated data received from patients at the 12-month follow-up visit which showed that three of the five patients who originally preferred their conventional strategy at the three-month experimental strategy visit switched their preference to HiRes. Thus, 48 of 50 patients (96%) ultimately preferred HiRes. |
P960058/S028 11/25/02 180-Day |
CLARION® CII Bionic Ear™ System HiFocus Electrode |
Advanced Bionics Corporation Sylmar, CA 91342 |
Approval for minor changes to the HiFocus Electrode to better facilitate the packing of the cochleostomy and electrode insertion. Specifically, the changes are to move the offset region approximately 3 mm further away from the current location. |
D970003/S018 11/4/02 Real-Time |
INSIGNIA Entra and Plus Implantable Pacemaker System |
Guidant Corporation St. Paul, MN 55112 |
Approval for modifications to the INSIGNIA Entra and Plus Implantable Pacemaker Systems as follow: 1) Disabling VRR in Entra devices; and 2) Correcting a math engine anomaly. |
P970037/S001 11/27/02 Special |
AutoDELFIA™ hAFP kit |
PerkinElmer Life Sciences, Inc. / PerkinElmer Wallac, Inc. 3985 Eastern Road Norton, OH 44203 |
Approval for labeling changes to the patient and physician brochures and 3 versions of the package insert for the laboratory. |
P970038/S005 11/27/02 180-Day |
Access Hybritech free PSA on the Access 2 Immunoassay Analyzer |
Beckman Coulter, Inc. Chaska, MN 55318 |
Approval for the Access Hybritech free PSA on the Access 2 Immunoassay Analyzer. The device is indicated for: The Access Hybritech free PSA assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of free prostate specific antigen (free PSA) in human serum using the Access Immunoassay Systems. Access Hybritech free PSA is intended to be used with Hybritech (total) PSA to calculate the ratio of free PSA to total PSA expressed as a percentage (percent free PSA). Percent free PSA as measured by the Hybritech assays is indicated for use as an aid in distinguishing prostate cancer from benign prostatic conditions, when used in conjunction with Hybritech (total) PSA for prostate cancer detection in men aged 50 years and older with total PSA between 4 and 10 ng/ml with digital rectal examination findings that are not suspicious for cancer. Prostatic biopsy is required for diagnosis of cancer. |
P970043/S011 11/7/02 180-Day |
LADARVision 4000 Excimer Laser System |
Alcon Laboratories, Inc. Orlando, FL 32826 |
Approval for a manufacturing site located at Alcon, Cork, Ireland. |
P970051/S021 11/22/02 180-Day |
Nucleus 24 Cochlear Implant System with Contour Softip Electrode |
Cochlear Americas Englewood, CO 80112 |
Approval for minor design modification to the Contour 24 cochlear implant electrode. The device, as modified, will be marketed under the trade name Contour Softip Electrode. |
P970061/S018 11/25/02 180-Day |
RADIUS Coronary Stent with Delivery System |
Boston Scientific Scimed, Inc. Maple Grove, MN 55311 |
Approval for an alternate sterililzation facility located at Cosmed Group, Inc. Coventry, Rhode Island. |
P980023/S009 11/25/02 180-Day |
Kainox RV-S and Kainox VCS ICD Leads |
Biotronik, Inc. Lake Oswego, OR 97035 |
Approval for the Kainox RV-S active fixation, single shock coil ICD lead and the Kainox VCS single shock coil ICD lead for use as an adjunct to modify the shock configuration of ICD systems. Together with legally marketed BIOTRONIK ICDs, these lead systems provide the patient with a system that is capable of detecting and treating ventricular tachyarrhythmias. |
P990017/S036 11/8/02 180-Day |
Ancure System |
Guidant Corporation Menlo Park, CA 94025 |
Approval for an additional sterilization site located at Steris Isomedix Services, Vega Alta, Puerto Rico. |
P990018/S003 11/6/02 Real-Time |
Menicon Z™ (tisilfocon A) Rigid Gas Permeable Contact Lens |
Menicon Co., Ltd. Aichi, Japan 460-0006 |
Approval for Alcon® Unique-pH Multi-Purpose Solution as an alternate wet shipping solution for the Menicon Z™ Rigid Gas Permeable Contact Lens. |
P990020/S009 11/21/02 180-Day |
The AneuRx™ Stent Graft with Xpedient Delivery System |
Peripheral Technologies Santa Rose, CA 95407 |
Approval for the Xpedient Delivery System. The device, as modified, will be marketed under the trade name AneuRx™ Stent Graft with Expedient Delivery System and is indicated for the endovascular treatment of infrarenal abdominal aortic or aorto-iliac aneurysms having: 1) Infrarenal, non-aneurysmal, neck length of greater than 1 cm at the proximal and distal ends of the aneurysm and an inner vessel diameter approximately 10-20% smaller than the labeled device diameter: 2) Morphology suitable for endovascular repair; 3) One of the following: a) Aneurysm diameter > 5 cm; b) Aneurysm diameter of 4-5 cm which has also increased in size by 0.5 cm in the last 6 months; or c) Aneurysm which is twice the diameter of the normal infrarenal aorta. |
P990025/S005 11/13/02 Real-Time |
NAVISTAR™ Deflectable Tip Diagnostic/Ablation Catheters |
Biosense Webster Diamond Bar, CA 91765 |
Approval for the sterilization facility located at Cosmed of California, San Diego, California. |
P990028/S005 11/25/02 Special |
FocalSeal-L Synthetic Absorbable Sealant |
Genzyme Biosurgery Cambridge, MA 02139 |
Approval for the addition of a box around the Contraindications section of the Instructions for Use for FocalSeal-L Sealant. |
P990034/S003 11/08/02 180-Day |
Isomed Implantable Constant-Flow Infusion Pump (Model 8472) |
Medtronic Neurological Minneapolis, MN 55432 |
Approval for a new manufacturing, packaging and sterilization facility at Medtronic Neurological and Spinal Division, Columbia Heights, Minnesota. |
P990042/S004 11/14/02 180-Day |
DiaSorin ETI-AB-AUK PLUS Assay |
DiaSorin, Inc. Baldwin, MD 21013 |
Approval for use of ETI-AB-AUK PLUS assay on the Biochem Immunosystems Labotech/ETI-LAB automated instrument. |
P990053/S008 11/25/02 180-Day |
OxiFirst™ Fetal Oxygen Saturation Monitoring System |
Tyco Healthcare /Nellcor Puritan Bennett Pleasanton, CA 94588 |
Approval for a new manufacturing facility located at Nellcor Puritan Bennett, Inc., Minneapolis, Minnesota. Factory service operations for the N-400 Fetal Oxygen Saturation Monitors will be performed at this facility. |
P990053/S009 11/25/02 180-Day |
OxiFirst™ Fetal Oxygen Saturation Monitoring System |
Tyco Healthcare /Nellcor Puritan Bennett Pleasanton, CA 94588 |
Approval for a new manufacturing facility located at Nellcor Puritan Bennett, Inc., Minneapolis, Minnesota. This facility will perform manufacturing of the FSp02-PM Fetal Patient Modules. |
P990053/S010 11/15/02 Special |
OxiFirst™ Fetal Oxygen Saturation Monitoring System |
Tyco Healthcare /Nellcor Puritan Bennett Pleasanton, CA 94588 |
Approval for modifications to the labeling. |
P990066/S015 11/21/02 180-Day |
Senographe 2000D Full Field Digital Mammography System |
General Electric Medical Systems Milwaukee, WI 53188 |
Approval for modifications to the approved system to permit use of an optional contrast enhancement algorithm (Dynamic Range Management) introduction of new display protocols and minor changes in the display scenarios, and addition of keyboard shortcuts for window width/window level settings. The supplement also includes changes in the labeling to reflect the modifications listed above. |
P990081/S001 11/27/02 180-Day |
PATHWAY HER2 (Clone CB11) |
Ventana Medical Systems, Inc. Tucson, AZ 85737 |
Approval for a new manufacturing site located at Ventana Medical Systems, Tucson, Arizona. |
P000018/S026 11/13/02 Special |
Novoste™ Beta-Cath™ 3.5F System |
Novoste Corp. Norcross, GA 30093 |
Approval for modifications to the User’s Manual, User’s Guide and customer training to include additional information on scenarios where the β-Rail 3.5F Delivery Catheter tip may be subjected to excessive force and the techniques for avoiding and/or resolving these scenarios. |
P000052/S012 11/18/02 180-Day |
GALILEO® III Intravascular Radiotherapy System |
Guidant Corporation Houston, TX 77054 |
Approval of the post-approval study for the device. |
P010013/S003 11/25/02 180-Day |
NovaSure Impedance Controlled Endometrial Ablation System |
Novacept, Inc. Palo Alto, CA 94303 |
Approval for a new manufacturing facility located at Sanmina-SCI Corporation, San Jose, California. The Novacept RF Controller will be manufactured at this facility. |
P010038/S002 11/20/02 Real-Time |
iCAD |
iCAD, Inc. Tampa, FL 33634 |
Approval
for a device name change from “MammoReader” to “iCAD.” |
P010049/S003 11/27/02 180-Day |
QuickSeal CCS Arterial Closure System |
Sub-Q, Inc. San Clemente, CA 92673 |
Approval for an alternate manufacturing facility to perform device assembly and packaging, located at Sub-Q, Inc., San Clemente, California. |
30-Day Notices (135 Day Supplement was not required)
P790019/S016 11/6/02 |
Abbott HAVAB-M™ EIA (List Number 9843) |
Abbott Laboratories, Inc. Abbott Park, IL 60064 |
Changes to: 1) Replace lyophilized goat anti-human IgM purchased from Litton Bionetics with non-lyophilized goat anti-human IgM purchased from Jackson Immuno Research. 2) Replace rheophoresis testing for goat anti-human IgM (antibody) identity/specificity with immunoelectro-phoresis (IEP) testing. 3) Replace HAVAB-M RIA (radioimmunoassay) antibody bead coat efficacy testing with small-scale antibody dilution factor determination and confirmation testing using HAVAB-M EIA (enzyme immunoassay) to establish the optimal dilution factor of the goat anti-human IgM antibody to be used for full-scale production bead coating. |
P890014/S004 11/8/02 |
DiaSorin ETI-HA-IGMK PLUS |
DiaSorin S.r.l. Saluggia, Italy 13040 |
Change in the vendor of the bulk solution used in the preparation of the Chromagen/ Substrate kit reagent with an accompanying change in the Stop Solution concentration. |
P890019/S007 11/8/02 |
DiaSorin ETI-AB-HAVK PLUS |
DiaSorin S.r.l. Saluggia, Italy 13040 |
Change in the vendor of the bulk solution used in the preparation of the Chromagen/ Substrate kit reagent with an accompanying change in the Stop Solution concentration. |
P990038/S003 11/8/02 |
DiaSorin ETI-MAK-2 PLUS |
DiaSorin S.r.l. Saluggia, Italy 13040 |
Change in the vendor of the bulk solution used in the preparation of the Chromagen/ Substrate kit reagent with an accompanying change in the Stop Solution concentration. |
P990041/S002 11/8/02 |
DiaSorin ETI-AB-EBK PLUS |
DiaSorin S.r.l. Saluggia, Italy 13040 |
Change in the vendor of the bulk solution used in the preparation of the Chromagen/ Substrate kit reagent with an accompanying change in the Stop Solution concentration. |
P990042/S005 11/26/02 |
DiaSorin ETI-AB-AUK PLUS |
DiaSorin S.r.l. Saluggia, Italy 13040 |
Change in the vendor of the bulk solution used in the preparation of the Chromagen/ Substrate kit reagent with an accompanying change in the Stop Solution concentration. |
P990043/S003 11/8/02 |
DiaSorin ETI-EBK PLUS |
DiaSorin S.r.l. Saluggia, Italy 13040 |
Change in the vendor of the bulk solution used in the preparation of the Chromagen/ Substrate kit reagent with an accompanying change in the Stop Solution concentration. |
P990044/S002 11/8/02 |
DiaSorin ETI-CORE-IGMK PLUS |
DiaSorin S.r.l. Saluggia, Italy 13040 |
Change in the vendor of the bulk solution used in the preparation of the Chromagen/ Substrate kit reagent with an accompanying change in the Stop Solution concentration. |
P990045/S003 11/8/02 |
DiaSorin ETI-AB-COREK PLUS |
DiaSorin S.r.l. Saluggia, Italy 13040 |
Change in the vendor of the bulk solution used in the preparation of the Chromagen/ Substrate kit reagent with an accompanying change in the Stop Solution concentration. |
P000011/S007 11/14/02 |
BiodivYsio® OC and SV Over-the-Wire Stent Delivery Systems |
Abbott Vascular Devices Redwood City, CA 94063 |
Change in vendor for the balloon material. |
P020009/S002 11/5/02 |
Express/ Express2™ Coronary Stent System |
Boston Scientific/ SCIMED Maple Grove, MN 55311 |
Changing the quality control acceptance criteria for the stainless steel tubing (raw material) used to manufacture the stent component for the devices. |
Summary of PMA Originals & Supplements Approved
Originals: 4
Supplements: 40
Summary of PMA Originals Under Review
Total Under Review: 68
Total Active: 39
Total On Hold: 29
Number Greater Than 180 Days: 1
Summary of PMA Supplements Under Review
Total Under Review: 252
Total Active: 150
Total On Hold: 102
Number Greater Than 180 Days: 1
Summary of All PMA Submissions Received
Originals: 3
Supplements: 76
Summary of PMA Supplement PMA Approval/Denial Decision Times
Number of Approvals: 40
Number of Denials: 0
Average Days Fr Receipt to Decision (Total Time): 108
FDA Time: 56.5 Days MFR Time: 51.5 Days
Updated 12/20/2002
CDRH Home Page | CDRH A-Z Index | Contact CDRH | Accessibility | Disclaimer
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page
Center for Devices and Radiological Health / CDRH